Key result
In patients undergoing saphenous vein graft intervention, sirolimus-eluting stents showed similar rates of non-Q-wave myocardial infarction compared to paclitaxel-eluting stents (4.3% vs 7.1%, P=0.55).
Why the study?
Do sirolimus-eluting stents compared to paclitaxel-eluting stents improve clinical outcomes in patients undergoing saphenous vein graft intervention?
Cohort (n=89)
Do sirolimus-eluting stents compared to paclitaxel-eluting stents improve clinical outcomes in patients undergoing saphenous vein graft intervention?
Absolute Event Rate: 4.3% vs 7.1%
p-value: p=0.55
Sirolimus-eluting stents and paclitaxel-eluting stents demonstrate similar safety and efficacy up to 6 months in saphenous vein graft interventions when used with distal protection devices.
No takes yet. Share an insight, caveat, or question.
Similar safety in SVG PCI does not yet support preferential stent choice; leaves open optimal selection pending randomized trials.
Chu et al. (2006) conducted a cohort in Saphenous vein graft (SVG) lesions (n=89). Sirolimus-eluting stents (SES) vs. Paclitaxel-eluting stents (PES) was evaluated on Non-Q-wave myocardial infarction (p=0.55). In patients undergoing saphenous vein graft intervention, sirolimus-eluting stents showed similar rates of non-Q-wave myocardial infarction compared to paclitaxel-eluting stents (4.3% vs 7.1%, P=0.55).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: